On track for full commercial launch in the U.S. in late June
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing
novel medicines to treat life-altering central nervous system (CNS)
disorders, today announced that the U.S. Drug Enforcement Administration
(DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of
the Controlled Substances Act. ZULRESSO, which was approved by the U.S.
Food and Drug Administration (FDA) on March 19, 2019, is the first and
only treatment specifically approved for postpartum depression (PPD),
the most common medical complication of childbirth.
With this decision, the product label for ZULRESSO will be finalized.
The Company expects to launch ZULRESSO in late June as planned. ZULRESSO
is administered via continuous intravenous (IV) infusion for 2.5 days
under the supervision of healthcare providers in sites of care certified
under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS)
program. The one-time infusion offers the potential for rapid resolution
of depressive symptoms of PPD.
“Historically, women suffering from PPD may have avoided seeking help
because of the stigma, lack of a specifically approved treatment and the
complicated journey to care – challenges that have been difficult for
women with PPD and their families to overcome,” said Mike Cloonan, chief
business officer at Sage. “Sage is taking on those challenges and
creating a family-centric approach to ZULRESSO availability by enabling
pathways to care including building our patient support organization,
where we will provide a range of meaningful support resources to women
with PPD and their families to help navigate the ZULRESSO treatment
journey. We also continue to activate Centers of Excellence across the
country with the goal of supporting a positive patient experience and
broad availability to ZULRESSO for women with PPD.”
The Company continues to focus on identifying and activating Centers of
Excellence (COE) and other healthcare settings capable of administering
ZULRESSO to women with PPD. The key criteria for identifying a potential
COE or other sites of care include: a PPD healthcare provider champion;
the ability to secure appropriate payer reimbursement for ZULRESSO; and
the capability to meet the requirements for certification under the
ZULRESSO REMS, which includes monitoring by qualified trained staff,
adherence to specific protocols and the maintenance of a patient
registry. The Company continues to execute against its planned
go-to-market strategy with a focus on the commercial launch of ZULRESSO
in late June.
For more information on ZULRESSO, including the final product label,
About Postpartum Depression
Postpartum depression (PPD) is
the most common medical complication of childbirth. PPD is a distinct
and readily identified major depressive episode that can occur during
pregnancy or after giving birth. Expert opinions vary as to the timing
of the onset of PPD, ranging from onset during pregnancy up to 4-weeks
postpartum and onset during pregnancy up to 12-months postpartum. PPD
may have devastating consequences for a woman and for her family, which
may include significant functional impairment, depressed mood and/or
loss of interest in her newborn, and associated symptoms of depression
such as loss of appetite, difficulty sleeping, motor challenges, lack of
concentration, loss of energy and poor self-esteem. PPD can be a
life-threatening condition due to the risk of suicide, a leading cause
of maternal death following childbirth. PPD is estimated to affect
approximately one in nine women who have given birth in the U.S. and
400,000 women annually. More than half of these cases may go undiagnosed
without proper screening.
About ZULRESSO™ (brexanolone) injection
ZULRESSO, the first
medicine specifically approved by the U.S. Food and Drug
Administration (FDA) for the treatment of postpartum depression (PDD) in
adults, is a positive allosteric modulator of both synaptic and
extrasynaptic GABAA receptors. Allosteric modulation of
neurotransmitter receptor activity results in varying degrees of desired
activity rather than complete activation or inhibition of the receptor.
What is ZULRESSO?
ZULRESSO™ (brexanolone) CIV is a prescription medicine used in adults to
treat a certain type of depression called Postpartum Depression.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ZULRESSO?
ZULRESSO can cause serious side effects, including:
Excessive sedation and sudden loss of consciousness. ZULRESSO
may cause you to feel very sleepy (excessive sedation) or pass out
(loss of consciousness). Your healthcare provider should check you for
symptoms of excessive sleepiness every 2 hours while you are awake.
During your ZULRESSO infusion, tell your healthcare provider right
away if you feel like you cannot stay awake during the time you
are normally awake or if you feel like you are going to pass out.
Your healthcare provider may lower your dose or stop the infusion
until symptoms go away.
You must have a caregiver or family member with you to help care
for your child(ren) during your ZULRESSO infusion.
- During your ZULRESSO infusion, tell your healthcare provider right
Because of the risk of serious harm resulting from excessive sedation
or sudden loss of consciousness, ZULRESSO is only available through a
restricted program called the ZULRESSO REMS.
Before receiving ZULRESSO, tell your healthcare provider about all
your medical conditions, including if you:
- drink alcohol
- have kidney problems
are pregnant or think you may be pregnant. It is not known if ZULRESSO
will harm your unborn baby.
There is a pregnancy registry for females who are exposed to
ZULRESSO during pregnancy. The purpose of the registry is to
collect information about the health of females exposed to
ZULRESSO and their baby. If you become pregnant during treatment
with ZULRESSO, talk to your healthcare provider about registering
with the National Pregnancy Registry for Antidepressants at
1-844-405-6185 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/
- There is a pregnancy registry for females who are exposed to
are breastfeeding or plan to breastfeed. ZULRESSO passes into breast
milk. Talk to your healthcare provider about the risks and benefits of
breastfeeding and about the best way to feed your baby while receiving
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
ZULRESSO and some medicines may interact with each other and cause
serious side effects.
Especially tell your healthcare provider if you take other
antidepressants, opioids, or Central Nervous System (CNS) depressants
(such as benzodiazepines).
Know the medicines you take. Keep a list of them to show your healthcare
provider and pharmacist when you get a new medicine. Your healthcare
provider will decide if other medicines can be taken with ZULRESSO.
How will I receive ZULRESSO?
ZULRESSO is given to you by continuous intravenous (IV) infusion into
your vein. The infusion will last for a total of 60 hours (2.5 days).
What should I avoid while receiving ZULRESSO?
ZULRESSO may make you feel dizzy and sleepy. Do not drive a car or do
other dangerous activities after your ZULRESSO infusion until your
feeling of sleepiness has completely gone away. See “What is the
most important information I should know about ZULRESSO?”
- Do not drink alcohol while receiving ZULRESSO.
What are the possible side effects of ZULRESSO?
ZULRESSO can cause serious side effects, including:
See “What is the most important information I should know about
Increased risk of suicidal thoughts or actions. ZULRESSO and
other antidepressant medicines may increase suicidal thoughts and
actions in some people 24 years of age and younger. Depression or
other serious mental illnesses are the most important causes of
suicidal thoughts or actions.
How can I watch for and try to prevent suicidal thoughts and actions?
Pay close attention to any changes, especially sudden changes in mood,
behavior, thoughts, or feelings, or if you develop suicidal thoughts
Tell your healthcare provider right away if you have any new or sudden
changes in mood, behavior, thoughts, or feelings.
Keep all follow-up visits with your healthcare provider as scheduled.
Call your healthcare provider between visits as needed, especially if
you have concerns about symptoms.
Tell your healthcare provider right away if you have any of the
following symptoms, especially if they are new, worse, or worry you:
Attempts to commit suicide, thoughts about suicide or dying, new or
worse depression, other unusual changes in behavior or mood
The most common side effects of ZULRESSO include:
- Sleepiness, dry mouth, passing out, flushing of the skin or face.
These are not all the side effects of ZULRESSO.
Call your doctor for medical advice about side effects. You may report
side effects to FDA at 1-800-FDA-1088.
Please see Full
Prescribing Information including Boxed Warning and Medication
Guide for ZULRESSO™ and discuss any questions you may have with
your healthcare provider.
About Sage Therapeutics
Sage Therapeutics is a
biopharmaceutical company committed to developing novel medicines to
transform the lives of patients with life-altering CNS disorders.
ZULRESSO™ (brexanolone) injection is a rapidly acting GABA modulator now
approved by the U.S. Food and Drug Administration as the first and only
treatment specifically indicated for postpartum depression. Sage is
developing a portfolio of novel product candidates targeting critical
CNS receptor systems, including SAGE-217, which is in Phase 3
development in major depressive disorder and postpartum depression. For
more information, please visit www.sagerx.com.
Various statements in this
release concern Sage’s future expectations, plans and prospects,
including without limitation: our expectations regarding the timing of
availability and launch of ZULRESSO in the treatment of PPD; our plans
regarding commercial activities and patient support; our expectations
regarding availability of REMS-certified sites of care for the
administration of ZULRESSO; our expectations regarding access to
treatment for women with PPD; our statements regarding the potential
benefit of ZULRESSO in the treatment of PPD; our estimates as to the
number of women who suffer from PPD; and other statements regarding the
potential and our plans and expectations for ZULRESSO and our other
programs and business. These statements constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are neither promises nor guarantees of future performance,
and are subject to a variety of risks and uncertainties, many of which
are beyond our control, which could cause actual results to differ
materially from those contemplated in these forward-looking statements,
including the risks that: availability and launch of ZULRESSO may not
occur on the timelines we expect; we may encounter issues or other
challenges in launching and commercializing ZULRESSO, including issues
related to market acceptance by healthcare providers, healthcare
settings and women with PPD, issues related to availability of sites of
care, challenges with reimbursement, other issues related to
limitations on the site of administration of ZULRESSO to REMS-certified
supervised healthcare settings and the other requirements of the REMS,
and challenges associated with execution of our marketing, sales and
patient support activities, which in each case could limit the potential
of ZULRESSO; results achieved with use of ZULRESSO in the treatment of
PPD once we have launched the product may be different than observed in
clinical trials, and may vary among patients; the number of women with
PPD or the unmet need for additional treatment options may be
significantly smaller than we expect; we may encounter unexpected safety
or tolerability issues with ZULRESSO or any of our product candidates;
we may encounter supply issues with respect to ZULRESSO or any of our
product candidates; we may not be successful in our development of any
of our current or future product candidates in any indication we are
currently pursuing or may in the future pursue; success in early stage
clinical trials may not be repeated or observed in ongoing or future
studies of any of our product candidates; ongoing and future clinical
results may not support further development or be sufficient to gain
regulatory approval of our product candidates; we may decide that a
development pathway for one of our product candidates in one or more
indications is no longer feasible or advisable or that the unmet need no
longer exists; the FDA may decide that the development program for any
of our product candidates, even if positive, is not sufficient for a new
drug application filing or approval; and we may encounter technical and
other unexpected hurdles in the commercialization of ZULRESSO or in the
development of our product candidates; as well as those risks more fully
discussed in the section entitled “Risk Factors” in our most recent
report filed with the Securities and Exchange Commission (SEC), and
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the SEC. In addition, any
forward-looking statements represent our views only as of today, and
should not be relied upon as representing our views as of any subsequent
date. We explicitly disclaim any obligation to update any
Maren Killackey, 617-949-4113
Alexis Smith, 617-588-3740